Reported about 8 hours ago
GSK Plc plans a £2 billion ($2.5 billion) share buyback, reflecting increased optimism about its drug pipeline and raising its sales forecast for 2031 to over £40 billion. The company reported better-than-expected fourth-quarter earnings, driven by advances in oncology medicines and growth in specialty drugs, despite concerns about vaccine sales and ongoing litigation over its former reflux medication, Zantac. The buyback will occur over the next 18 months, as GSK focuses on expanding its research and development in key therapeutic areas.
Source: YAHOO